Obesity and inflammation: the linking mechanism and the complications

Mohammed S. Ellulu1, Ismail Patimah2, Huzwah Khaza’ai2, Asmah Rahmat3, Yehia Abed4

1Department of Nutrition and Dietetics, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM), Serdang, Malaysia
2Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM), Serdang, Malaysia
3Cancer Resource and Educational Centre (CARE), Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM), Malaysia
4Faculty of Public Health, Al Quds University of Gaza, Palestine

Submitted: 23 October 2015
Accepted: 28 December 2015

Arch Med Sci 2017; 13, 4: 851–863
DOI: https://doi.org/10.5114/aoms.2016.58928
Copyright © 2016 Termedia & Banach

Abstract

Obesity is the accumulation of abnormal or excessive fat that may interfere with the maintenance of an optimal state of health. The excess of macronutrients in the adipose tissues stimulates them to release inflammatory mediators such as tumor necrosis factor α and interleukin 6, and reduces production of adiponectin, predisposing to a pro-inflammatory state and oxidative stress. The increased level of interleukin 6 stimulates the liver to synthesize and secrete C-reactive protein. As a risk factor, inflammation is an imbedded mechanism of developed cardiovascular diseases including coagulation, atherosclerosis, metabolic syndrome, insulin resistance, and diabetes mellitus. It is also associated with development of non-cardiovascular diseases such as psoriasis, depression, cancer, and renal diseases. On the other hand, a reduced level of adiponectin, a significant predictor of cardiovascular mortality, is associated with impaired fasting glucose, leading to type-2 diabetes development, metabolic abnormalities, coronary artery calcification, and stroke. Finally, managing obesity can help reduce the risks of cardiovascular diseases and poor outcome via inhibiting inflammatory mechanisms.

Key words: obesity, inflammation, interleukin 6, C reactive protein, adiponectin, linking mechanism.

Introduction

Inflammation is an ordered sequence of events engineered to maintain tissue and organ homeostasis. The timely release of mediators and expression of receptors are essential to complete the program and restore tissues to their original condition [1]. Additionally, inflammation is a protective tissue response to injury or destruction of tissues that serves to destroy or dilute both the injurious agent and the injured tissues [2].

There are two types of inflammation; the first is acute inflammation that lasts for a short time and is characterized by edema and migration of leukocytes, and the second one is chronic inflammation that lasts for a long time and is characterized by the presence of lymphocytes and macrophages and the proliferation of blood vessels and connective tissue [3].
It is considered a characteristic feature of metabolic syndrome [4], characterized by secretion of inflammatory adipokines usually from adipose tissue, such as leptin, interleukin (IL-6), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1), and resistin [5]. Obesity, which is a feature of metabolic syndrome, was associated with chronic inflammation in obese subjects [6]. This review discusses the association of a number of inflammatory indicators with obesity, and sheds light on the associated health complications. Inflammatory indicators include IL-6 and C-reactive protein (CRP) as inflammatory markers, and adiponectin as an anti-inflammatory marker.

### Interleukin 6

Interleukin 6 is a cytokine produced by many different cell types, including immune cells and adipose tissue, that mediates inflammatory responses [7]. The IL-6 receptor is also expressed in several regions of the brain, such as the hypothalamus, in which it controls appetite and energy intake, where it has a role in the regulation of energy homeostasis via suppressing lipoprotein lipase activity [8].

Unlike other cytokines, IL-6 is unusual in that its major effects take place at sites distinct from its origin and are consequent upon its circulating concentrations. For this reason, it is called the endocrine cytokine [9]. IL-6 exerts its action primarily by binding to the membrane-bound α receptor IL-6R. Subsequently, the IL-6/IL-6R complex associates with glycoprotein 130 (gp130), leading to gp130-homodimer formation and signal initiation [10].

### Obesity and IL-6

Obesity is considered a characteristic feature of metabolic syndrome [4]. The link between them has been attributed to the inflammatory process [6]. Obesity became a feature among rural populations like urban, as seen in Iran [11]. Obesity results from an imbalance between energy intake and expenditure, which means a positive energy balance [12]. The adipose tissue can be divided into two major types: brown and white adipose tissue [13]. In newborn humans, brown adipose tissue helps regulate energy expenditure by thermogenesis mediated by the expression of uncoupling protein-1 (UCP1) [14]. In adult humans, the amount of brown adipose tissue is inversely correlated to body mass index (BMI), especially in older people, suggesting a potential role of brown adipose tissue in adult human metabolism [14].

On the other hand, white adipose tissue is no longer considered an inert tissue mainly devoted to energy storage but is emerging as an active participant in regulating physiologic and pathologic processes, including immunity and inflammation [15]. Macrophages are components of adipose tissue and actively participate in its activities. Furthermore, cross-talk between lymphocytes and adipocytes can lead to immune regulation [16]. Adipose tissue produces and releases a variety of pro-inflammatory and anti-inflammatory factors, including the adipokines leptin, adiponectin, and resistin, as well as cytokines and chemokines, such as TNF-α, IL-6, and MCP-1 [5].

Positive associations between different measures of obesity and plasma IL-6 levels have been described [17]. It has been calculated that one third of total circulating concentrations of IL-6 originate from adipose tissue [18].

The overexpressed pro-inflammatory cytokines in obesity are considered the link between obesity and inflammation [19]. Adipose tissue responds to stimulation of extra nutrients via hypertrophy and hypertrophy of adipocytes. The nature of adipose tissue is heterogeneous, including endothelium, immune cells, and adipocytes [20]. With progressive adipocyte enlargement and obesity, the blood supply to adipocytes may be reduced, leading to hypoxia [21].

Hypoxia is proposed to be an inciting etiology of necrosis and macrophage infiltration into adipose tissue, which leads to overproduction of pro-inflammatory mediators. This results in localized inflammation in adipose tissue that propagates overall systemic inflammation associated with the development of obesity-related comorbidities [22]. Amongst inflammatory mediators, three are produced by macrophages: TNF-α, IL-6, and adiponectin [15]. Furthermore, IL-6 strongly stimulates hepatocytes to produce and secrete CRP, indicating a state of inflammation [23]. Ellulu et al. [24] linked abdominal obesity with metabolic abnormalities via the inflammatory process; Figure 1 presents their illustration of it [24].

Moreover, accumulation of free fatty acids in obesity activates pro-inflammatory serine kinase cascades, such as IκB kinase and c-Jun N-terminal kinase, which in turn promotes adipose tissue to release IL-6 that triggers hepatocytes to synthesize and secrete CRP [25].

Illán-Gómez et al. [26] evaluated the inflammatory mediators in morbidly obese patients after undergoing bariatric surgery. Levels of IL-6 significantly decreased after 12 months of surgery. IL-6 correlated significantly with BMI ($r = 0.53$, $p < 0.001$), and IL-6 was associated with high levels of CRP. Arnardottir et al. [27] assessed the interaction between obstructive sleep apnea with obesity in IL-6 individuals aged + 50 years. Patients were categorized into three groups based on BMI (<30, 30–35, and ≥35 kg/m²), and IL-6 was distributed as follows: 1.3, 1.6, and 2.2 pg/ml, respectively, indicating the strong association of IL-6 with BMI.
Obesity and inflammation: the linking mechanism and the complications

Fontana et al. [18] tested the level of IL-6 and other inflammatory markers between the portal vein and peripheral artery among 25 morbidly obese patients who underwent gastric bypass surgery in St. Louis, Missouri. The study hypothesized that visceral fat promotes systemic inflammation by secreting inflammatory adipokines into the portal circulation that drains visceral fat. Mean plasma IL-6 concentration was about 50% greater in the portal vein than in the peripheral artery \( (p = 0.007) \). Additionally, the study showed that portal vein IL-6 concentration correlated directly with systemic CRP concentrations \( (r = 0.544, p = 0.005) \).

Wannamethee et al. [28] examined the association of IL-6 with metabolic abnormalities among non-diabetic elderly British individuals. After adjusting for age, levels of IL-6 increased by increasing both BMI and waist circumference (WC). Means of IL-6 were 2.23, 2.39, and 2.61 pg/ml; they were associated respectively with BMI: < 25.08, 25.08–27.79, and \( \geq 27.8 \) kg/m². Similarly for WC, means of IL-6 were 2.23, 2.33, and 2.69 pg/ml, and were associated respectively with WC: < 92.4, 92.4–100.1, and \( \geq 100.2 \) cm.

Warnberg et al. [29] designed a study to clarify the association between BMI and low-grade inflammation in Spanish adolescents. Levels of IL-6 showed an elevation with increased BMI in both males and females, and the same results were achieved for TNF-\( \alpha \) for both genders.

Complications of IL-6

Circulating inflammatory mediators including IL-6 have been hypothesized to play a substantial role in the development and alteration of several diseases [30–32]. IL-6 is a key cytokine in the acute-phase inflammatory response that stimulates CRP and fibrinogen production in the liver, release of white blood cells and platelets from bone marrow, and activation of endothelium and hemostasis [32]. Table I summarizes complications associated with increased IL-6 levels, accompanied by other markers, particularly CRP [33–51].

C-reactive protein

C-reactive protein is a sensitive marker of systemic inflammation that is synthesized by the liver. C-reactive protein is a nonspecific acute-phase reactant that has traditionally been used to detect acute injury infection and inflammation [52].

Biomedical evaluation of CRP

The risk categories were established by the American Heart Association (AHA) and the Centers for Disease Control and Prevention (CDC) in 2003. The level of CRP should be less than 1.0 mg/l to reduce the inflammatory risk of metabolic diseases. A very high level of CRP \( (\geq 10.0 \text{ mg/l}) \) indicates an infection status, and the test should be removed from epidemiological studies [53], and it should be repeated after 2 weeks of infection treatment [54]. Additionally, the stable and repeated elevated level of CRP for a while \( (\geq 10.0 \text{ mg/l}) \) suggests that the condition is more likely to be chronic rather than acute inflammation [53]. Categories of CRP are shown in Table II.

According to the AHA and the CDC in 2002, the CRP test is a simple blood test that carries no risks, but could be affected by medications and other factors. Hormone therapy, pregnancy, birth control pills, and chronic inflammation (such as arthritis) can raise CRP levels. Cholesterol-lowering statin drugs and anti-inflammatory drugs (such as aspirin, ibuprofen, diclofenac, and naproxen) may lower CRP levels [54].
Table 1. Complications of elevated IL-6

| Authors                  | Biochemical factors                      | Complications                                      |
|--------------------------|------------------------------------------|----------------------------------------------------|
| Cardiovascular diseases: |                                         |                                                    |
| Adar et al. [33]         | IL-6, CRP, fibrinogen                    | Atherosclerosis and coagulation                     |
| Sarvottam and Yadav [34] | IL-6, adiponectin, endothelin-1          | Cardio-metabolic risks                              |
| Chen et al. [35]         | Adiponectin, IL-6, CRP, oxidative stress | Metabolic syndrome                                 |
| Danesh et al. [31]       | IL-6, CRP                                | Coronary heart disease                              |
| Wannamethee et al. [28]  | IL-6, CRP, FBG, TC, TG, HDL-c, fibrinogen, BP | Cardiovascular disease                            |
| Von Eynatten et al. [36] | IL-6, CRP, FBG, BP, adiponectin          | Heart failure                                       |
| Hansson [32]             | IL-6                                     | Coronary artery disease                             |
| Fernandez-Real et al. [37]| IL-6, CRP, BP, TG, FBG                   | Atherosclerosis, insulin resistance, blood pressure|
| Pradhan et al. [38]      | IL-6, CRP                                | T2DM                                               |
| Ridker et al. [39]       | IL-6                                     | Myocardial infarction                               |
| Cancer diseases:         |                                         |                                                    |
| Taniguchi and Karin [40] | IL-6                                     | Colorectal and gastric cancers                      |
| Zhou et al. [41]         | IL-6, CRP                                | Lung cancer                                        |
| Sansone and Bromberg [30]| IL-6                                     | Metastatic progression                              |
| Ara and DeClerck [42]    | IL-6                                     | Bone metastasis and cancer                          |
| Other diseases:          |                                         |                                                    |
| Matura et al. [43]       | IL-6                                     | Pulmonary hypertension                              |
| Giuba et al. [44]        | IL-6, TNF-α, leptin, TG, TC, BMI, WHR, BP| Chronic renal diseases                              |
| Arnardottir et al. [27]  | IL-6, CRP                                | Obstructive sleep apnea                             |
| Fujishima et al. [45]    | IL-6, IL-17F                             | Induction of IL-6 in keratinocytes causes inflammation in psoriasis |
| Gabay [46]               | IL-6                                     | Rheumatoid arthritis                                |
| Di Cesare et al. [47]    | IL-6                                     | Periprosthetic infection in patients undergoing a reoperation at the site of a total hip or knee arthroplasty |
| Arican et al. [48]       | IL-6, TNF-α, IL-8, IL-12, IL-18, IFN-γ | Active psoriatic patients have significantly higher levels of inflammatory mediators than controls |
| Musselman et al. [49]   | IL-6                                     | Depression                                          |
| Wirtz et al. [50]        | IL-6, CRP                                | Inflammation after total knee and hip arthroplasties|
| Elder et al. [51]        | IL-6                                     | IL-6 acts as an autocrine mitogen in psoriatic epidermis |

T2DM – type 2 diabetes mellitus, IL-6 – interleukin 6, CRP – C-reactive protein, TC – total cholesterol, TG – triglyceride, HDL-c – high-density lipoprotein cholesterol, FBG – fasting blood glucose, BP – blood pressure, TNF-α – tumor necrosis factor α, BMI – body mass index, WHR – waist-to-hip ratio, MCP-1 – monocyte chemoattractant protein-1, IFN-γ – interferon γ. Increases of all previous plasma factors except adiponectin and HDL-c induce complications.

In 2002, the AHA and the CDC co-sponsored a conference and workshop on several laboratory-based inflammatory markers: adhesion molecules, cytokines, fibrinogen, CRP, serum, amyloid A, and the white blood cell count. The workshop participants concluded that, of the tests studied, the CRP test had the most desirable characteristics. Assays for some markers, such as
cytokines, were not sufficiently standardized for clinical use, and other markers that had reliable, commercially available assays, such as the white blood cells (WBC) count, were not as predictive or had not been demonstrated to be an independent predictor of CVD events. The conference recommended that, when CRP is used, it should be “measured twice, either fasting or non-fasting, with the average expressed in mg/l, in metabolically stable patients” [54].

C-reactive protein levels well below the conventional clinical upper limit of 1.0 mg/l have been associated with a 2- to 3-fold increase in risk of heart disease mortality in healthy adults. In a meta-analysis of seven prospective studies, elevated

### Table III. Complications of elevated CRP

| Authors            | Population                          | Outcomes                                                                 |
|--------------------|-------------------------------------|---------------------------------------------------------------------------|
| Vadakayil et al. [59] | Patients with chronic plaque psoriasis | Elevated levels of CRP are a useful marker of psoriasis severity, and may be an independent risk factor for CVD |
| Takahashi et al. [60] | Psoriasis vulgaris patients          | CRP level is increased in psoriasis, and can predict the future risk of cardio- and cerebrovascular disease |
| Ma et al. [61]      | Patients with large artery atherosclerosis and small artery occlusion had higher levels of CRP, fibrinogen, and CXCL16 (chemokine) |
| Köşüş et al. [62]   | Obese pregnant women are susceptible to the development of metabolic complications such as gestational diabetes mellitus, hypertension, and CVDs due to CRP and SCFT |
| Kurtoglu et al. [63] | Heart disease patients               | Increased risk of mitral annular calcification                             |
| Rajendran et al. [64] | Chennai population India             | Acute myocardial infarction                                               |
| Woodard et al. [65] | Women transitioning through menopause | Aortic stiffness                                                          |
| Lee et al. [66]     | T2DM (free of CVDs)                  | Major adverse cardiovascular events                                       |
| Kalhan et al. [67]  | Young adults                         | Abnormal lung functions                                                   |
| Den Hertog et al. [68] | Ischemic stroke patients            | Poor outcome or death                                                     |
| Devaraj et al. [69] | CRP impaired glycocalyx function “lines and protects endothelial luminal surface”, leading to endothelial dysfunction, resulting in atherogenesis |
| Cirillo et al. [70] | Metabolic syndrome and progressive renal disease |
| Hubel et al. [71]   | Pregnant women                       | Preeclampsia                                                              |
| Trichopoulos et al. [72] | CRP was a strong carcinogenic factor, associated with liver cancer, lymphoma, bladder cancer, leukemia |
| Erlinger et al. [73] | CRP strongly correlated with colorectal cancer |
| Seddon et al. [74]  | Geriatrics                           | Macular degeneration                                                     |
| Russell et al. [75] | Polymorphism at the CRP locus influences gene expression and predisposes to systemic lupus erythematosus |
| Sesso et al. [76]   | Prospective with normal BP in female aged ≥ 45 years | Hypertension |
| Stuveling et al. [77] | Renal disease patients              | Renal function loss due to glomerular hyperfiltration                     |
| Ridker [78]         |                                    | Heart attack and stroke                                                   |
| Han et al. [79]     | Prospective in Caucasians (Mexico), CRP predicted T2DM and metabolic syndrome in adults |
| Mallya et al. [80]  |                                    | CRP concentration closely reflects activity of rheumatoid arthritis       |

CVDs – cardiovascular diseases, T2DM – type 2 diabetes, CRP – C-reactive protein, BP – blood pressure, SCFT – subcutaneous abdominal fat thickness. The increases of CRP induce the complications.
serum CRP has been shown to predict future risk of CHDs [55]. Recent studies have shown a positive independent association between atherosclerotic events and CRP [52, 56, 57], which acts as a proatherosclerotic factor by up-regulating angiotensin type-1 receptor expression [58]. Some of the complications of elevated CRP concentration are presented in Table III [59–60].

**Obesity and CRP**

In 2010, a meta-analysis by the Emerging Risk Factors Collaboration identified that each increase of CRP by 1 standard deviation was associated with a 60% increase of vascular risk. Many cross-sectional studies have linked obesity with CRP [81]. Each degree of obesity was related directly to CRP, regardless of ethnicity characteristics and sex [82]. Also, a strong correlation was obtained by the meta-regression analysis between obesity and CRP in both adults and children.

The link between obesity and elevated serum level of CRP has been well explained by the pathophysiological mechanism. The central role of inflammation is attributed to the liver, as it drains free fatty acids, and circulating triacylglycerol promoting release of cytokines (IL-6) by adipose tissue, which in turn triggers hepatocyte expression and release of CRP [81]. The cross-sectional evidence addressed the link between obesity and CRP. Klisic et al. [83] measured CRP and metabolic markers among normal weight and overweight postmenopausal women in Montenegro. Significantly higher levels of CRP and triglyceride (TG) \( p = 0.005, p < 0.001; \) respectively) in overweight women were reported compared to normal weight women. Similarly, Dayal et al. [84] identified the role of anthropometric measurements with CRP in Indian children. By using a multiple logistic regression analysis, for each 1.0 unit increase in BMI, the odds ratio of CRP increased by 37% (95% CI: 1.23–1.53, \( p = 0.007 \)).

Steppich et al. [6] evaluated the association between inflammatory markers and obesity indices in normo- and hypertensive subjects; waist-to-height ratio (WHR), which is a sensitive index of visceral obesity, was associated with chronic inflammation in obese hypertensive subjects, and body adiposity index (BAI) correlated with CRP independently of hypertension and sex. Likewise, Kawamoto et al. [85] studied the association between BMI and CRP after considering the confounding factors by multiple linear regression analysis. Body mass index, age, smoking habits, and TG were significant predictors of CRP. In addition, Fontana et al. [18] evaluated the role of visceral adiposity in generating inflammation in extremely obese adults possessing BMI 54.7 ±12.6 kg/m², WC 150 ±10 cm, and aged 42 ±9 years. By considering the blood from the portal vein and radial artery, IL-6 was about 50% greater in the portal vein than in the radial artery \( (p = 0.007) \), and portal vein IL-6 correlated directly with systemic CRP \( r = 0.544, p = 0.005 \).

Klisic et al. [86] identified the prevalence of high CRP \( (\geq 3 \text{ mg/l}) \) among free diabetes or heart diseases, and normo-lipidemic adults in the USA. CRP was related directly to BMI: 31.4–35.1% for overweight participants, and 52.5–60.9% for obese participants. After omitting individuals with CRP \( \geq 10 \text{ mg/l} \), the adjusted prevalence of high CRP \( (\geq 3 \text{ mg/l}) \) was 14.4% for normal weight, 31.6% for overweight, and 36.0% for obese.

Subcutaneous abdominal fat thickness (SCFT) is important for predisposition to metabolic and cardiovascular diseases. In pregnant women between 24 and 28 weeks of gestation, Köşüş et al. [62] evaluated maternal SCFT and metabolic changes. The results indicated a significant association between SCFT and glycated haemoglobin (HbA\(_1c\)).. Whereas higher levels of CRP were found in 47.9% of cases with SCFT over 15 mm.

On the other hand, many factors such as age, gender, smoking, and sedentary lifestyle have correlated closely with CRP and systemic cytokine concentrations [54, 87, 88]. Furthermore, elevated CRP level may be associated with some pathological conditions and used as a marker for more severe conditions; e.g. high levels of CRP among patients with myocardial infarction may lead to left ventricular systolic dysfunction [89]. Sleep restriction was also correlated with cardiovascular diseases (CVD), because it was hypothesized to elevate CRP [90]. Likewise, obstructive sleep apnea was linked directly with the progression of CVDs, which has been associated significantly with high CRP levels and BMI [27].

Shivpuri et al. [91] identified the impact of chronic stress in major life domains (relationship, work, sympathetic-caregiving, financial) in worsening CRP in men and women aged > 45 years. Moreover, women showed a slight higher stress level than men. Along the same line, Kwon et al. [92] found that plasma level of CRP was significantly higher in patients with pulmonary hypertension (“systolic pulmonary artery pressure \( \geq 35 \text{ mm Hg} \)” than in individuals without hypertension.

**Molecular link of IL-6 and CRP**

C-reactive protein is synthesized and secreted primarily in human hepatocytes and is regulated mainly by IL-6 and IL-1 [23]. The induction of IL-6 and IL-1β could be inhibited by the farnesoid X receptor (FXR; NR1H4). FXR is a member of the nuclear hormone receptor superfamily that functions as a ligand-activated transcription factor and is highly expressed in the liver, intestine, kid-
ney and adrenal glands [93]. FXR regulates many genes involved in bile acid synthesis and lipid and lipoprotein metabolism [94]. FXR can be activated by physiological concentrations of bile acids [95], or by potent synthetic FXR ligands including GW4064, 6a-ethyl-chenodeoxycholic acid (6ECD-CA) and WAY-362450 [96]. Activation of FXR has been shown to induce eNOS expression in vascular endothelial cells and inhibit vascular smooth muscle cell inflammation by downregulation of inducible nitric oxide synthase and cyclooxygenase-2 expression [97]. Furthermore, an agonist for the nuclear receptor, liver X receptor, also inhibited IL-6/IL-1β-induced CRP expression in human hepatocytes. This was shown to be mediated through inhibition of cytokine-induced NCoR clearance from the CRP promoter [98].

Adiponectin

Adiponectin is a protein hormone derived from adipocytes that has gained considerable importance due to its positive impacts on inflammation [99], atherosclerosis, type 2 diabetes mellitus (T2DM), and insulin resistance [99–101]; thus, it links the adipose tissue directly with the cornerstones of metabolic abnormalities [102]. Adiponectin is a 247-amino acid peptide discovered in 1995 [103], which circulates at relatively high (2–20 µg/ml) serum concentrations [104], while Ouchi et al. [105] evaluated the levels typically ranging from 3–30 µg/ml, in normal human subjects.

In healthy non-metabolic subjects, adiponectin was accompanied by anti-inflammatory effects of T2DM, and reduced risk of atherosclerosis [106]. It increases local nitric oxide production, which in turn protects against endothelial dysfunction, and inhibits plaque initiation and thrombosis [107]. Thus it acts as a vasoprotective factor [108] and reduces oxidative stress [109]. In the liver, adiponectin improves insulin sensitivity, decreases uptake of non-esterified fatty acids, reduce gluconeogenesis, and increases the oxidation process [110]. Centrally, it has high potency in regulating weight gain and increasing energy expenditure [111].

In healthy adults with adiponectin levels within the upper 20% range, it was noted that they have 2-fold reduced risk of myocardial infarction [112], and have 7-fold reduced risk of progression of coronary artery calcification [113]. Figure 2 illustrates
the action of adiponectin on insulin sensitivity and peripheral tissues [114].

**Obesity and adiponectin**

Adiponectin plays an important autocrine or paracrine role, having “local effects”, which influence adipose tissue functions by overexpressing the Adipoq gene which increases fat tissue mass via an increased number of adipocytes rather than size [114].

Different studies proved that serum level of adiponectin is reduced significantly with weight gain and obesity [115]. Studies in humans identified the role of visceral adipocytes in secreting adiponectin and other adipokines more than subcutaneous adipocytes, even though the decreased level of adiponectin in obesity is still unclear [106]. However, there is an assumption supposed that the increased serum level of inflammatory mediators such as IL-6 and TNF-α that are secreted from adipocytes are responsible for inhibiting and reducing the synthesis and secretion of adiponectin [106], and thus, the endothelial well-being and its cardio-protective action will also be suppressed [102].

| Authors          | Population               | Outcome                                                                 |
|------------------|--------------------------|-------------------------------------------------------------------------|
| Narayan et al.   | T2DM                     | Myocardial infarction                                                   |
| Kanhai et al.    | Meta-analysis            | CHD and stroke                                                          |
| Kim et al.       | Meta-analysis            | Hypertension                                                            |
| Blaslov et al.   | T1DM                     | Metabolic abnormalities                                                 |
| Chen et al.      | In metabolic syndrome    | reduced activity of antioxidant enzyme (glutathione peroxidase), and increased oxidative stress markers (malondialdehyde) |
| Kim et al.       | Non-diabetic adults      | Impaired fasting glucose                                                |
| Ho et al.        | Women’s Health Study     | Peripheral artery disease                                               |
| Li et al.        | Meta-analysis            | T2DM                                                                    |
| Snijder et al.   | Hoorn Study (Netherlands)| Peripheral arterial stiffness                                           |
| Greif et al.     | CVD patients             | Coronary atherosclerosis                                                |
| Marso et al.     | Non-diabetic population  | Plaque composition in coronary artery                                   |
| Dekker et al.    | Hoorn Study (Netherlands)| Significant predictor of CVD mortality                                 |
| Qasim et al.     | Healthy, non-diabetic    | Coronary artery calcification                                           |
| Hanley et al.    | Non-diabetic Africans    | Negative association with adiposity and FBG level                       |
| Frystyk et al.   | Healthy elderly men      | Coronary heart disease                                                  |
| Von Eynatten et al. | In patients with CHD and heart failure patients, positive correlation with HDL-c and NT-proBNP (measure of left ventricular ejection fraction), negative correlation with TG | |

T1DM – type 1 diabetes mellitus, T2DM – type 2 diabetes mellitus, CHD – coronary heart disease, CVD – cardiovascular disease, IL-6 – interleukin 6, CRP – C-reactive protein, TG – triglyceride, HDL-c – high density lipoprotein cholesterol, FBG – fasting blood glucose, NT-proBNP – N-terminal of the prohormone brain natriuretic peptide. The decreases of the adiponectin and HDL-c levels and increases of all previous factors induce the complications.
Adiponectin was associated with decreased peripheral arterial stiffness, and also adiponectin was negatively associated with abdominal and total fat.

Dekker et al. [119] studied the impact of adiponectin in predicting CVDs and mortality in a population aged 50–75 years from the Hoorn Study. Adiponectin levels were divided into quartiles; the lowest quartile was associated with higher BMI, and the highest quartile was associated with lower BMI in significant trends in both men and women.

Jaleel et al. [120] compared the adiponectin level in normal weight and obese post-menopause women. The level of adiponectin was significantly reduced in obese subjects compared with normal weight ones. The study also showed that metabolic abnormalities are associated with obesity including lipid profile and leptin.

Complications associated with adiponectin

Hypoadiponectinemia (plasma level < 4.0 µg/ml) has been associated with increased levels of TG and FBG, decreased HDL-c, hypertension, and increased risk of metabolic syndrome [121]. The atherosclerosis risk was doubled by a low level of adiponectin [122]. Moreover, lower adiponectin has been associated with decreased low-density lipoprotein (LDL) particle size [123], and increased markers of systemic inflammation [105]. In addition, Dalamaga et al. [124] in a review linked it with many types of cancer based on epidemiological evidence. Table IV presents collected studies describing the complications of reduced levels of adiponectin and the main studied vascular and systemic diseases [125–136].

Conclusions

Sustained inflammation is considered a strong risk factor for developing many diseases including CVDs, metabolic syndrome, diabetes, and cancer. As a risk factor, obesity predisposes to a pro-inflammatory state via increased inflammatory mediators IL-6 and TNF-α, and reduced levels of adiponectin, which has totally anti-inflammatory function. According to Badawi et al. [137], TNF-α is overexpressed in the overweight state, while IL-6 is linked more to the obese state that influences the liver to synthesize and secrete CRP, which is a feature of systemic inflammation. This state is associated with reduced levels of adiponectin, which is important in improving insulin sensitivity, reducing metabolic abnormalities, and adjusting the energy expenditure. In addition, the inflammatory state followed by vascular and endothelial dysfunction is characterized by decreased nitric oxide and elevated reactive oxygen species leading to oxidative stress. Both statuses of oxidative stress and inflammation initiate atherosclerosis, hypertension, alteration of metabolic markers, and thus major adverse cardiovascular events.

Acknowledgments

The author expresses sincere thanks to the faculty of Medicine and Health Sciences, Universiti Putra Malaysia, for the use of the library.

Conflict of interest

The authors declare no conflict of interest.

References

1. Romano M. Inflammation resolution: does the bone marrow have a say? Am J Hematol 2008; 83: 435-6.
2. Feuerstein GZ, Libby P, Mann DL. Inflammation – a new frontier in cardiac disease and therapeutics. In: Inflammation and cardiac diseases. Feuerstein GZ, Libby P, Mann DL (eds.). Birkhäuser Basel 2003; 1-5.
3. Seki H, Tani Y, Arita M. Omega-3 PUFa derived anti-inflammatory lipid mediator resolv E1. Prostaglandins Other Lipid Mediat 2009; 89: 126-30.
4. Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 2004; 29: 439-43.
5. Lafontan M. Fat cells: afferent and efferent messages define new approaches to treat obesity. Annu Rev Pharmacol Toxicol 2004; 45: 119-46.
6. Stepień M, Stepień A, Wiazek RN, Paradowski M, Baran M, Rysz J. Obesity indices and inflammatory markers in obese non-diabetic normo- and hypertensive patients: a comparative pilot study. Lipids Health Dis 2014; 13: 29.
7. Brichory FM, Misek DE, Yim AM, et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A 2001; 98: 9824-9.
8. Stenlöf K, Wenstedt I, Fjallman T, Wallenius V, Wallenius K, Jansson JO. Interleukin-6 levels in the central nervous system are negatively correlated with fat mass in overweight/obese subjects. J Clin Endocrinol Metab 2003; 88: 4379-83.
9. Papanicolau DA, Vgontzas AN. Interleukin-6: the endocrine cytokine. J Clin Endocrinol Metab 2000; 85: 1331-2.
10. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011; 1813: 878-88.
11. Rahmanian M, Kelishadi R, Qorbani M, et al. Dual burden of body weight among Iranian children and adolescents in 2003 and 2010: the CASPIAN-III study. Arch Med Sci 2014; 10: 96-103.
12. Krzysztofek Z, Wierzejewska E, Zielińska A. Obesity. An analysis of epidemiological and prognostic research. Arch Med Sci 2015; 11: 24-33.
13. Curat CA, Miranville A, Sengenes C, et al. From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. Diabetes 2004; 53: 1285-92.
14. Cypess AM, Lehman S, Williams G, et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med 2009; 360: 1509-17.
15. Karastergiou K, Mohamed-Alli V. The autocrine and paracrine roles of adipokines. Mol Cell Endocrinol 2010; 318: 69-78.
16. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115: 911-9.
17. Straub RH, Hense HW, Andus J, Scholmerich J, Riegger AJ, Schunkert H. Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study. J Clin Endocrinol Metab 2000; 85: 1340-4.
18. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007; 56: 1010-3.
19. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-7.
20. Halberg N, Wernerstedt-Asterholm I, Scherer PE. The adipocyte as an endocrine cell. Endocrinol Metab Clin North Am 2008; 37: 753-68.
21. Cinti S, Mitchell G, Barbarelli P, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005; 46: 2347-55.
22. Trayhurn P, Wood I. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92: 347-55.
23. Zhang S, Liu Q, Wang J, Harnish DC. Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists. Biochem Biophys Res Commun 2009; 379: 476-9.
24. Ellulu MS, Khaza’ai H, Abed Y, Rahmat A, Ismail P, Ranney Y. Role of fish oil in human health and possible mechanism to reduce the inflammation. Inflammopharmacology 2015; 23: 79-89.
25. Rocha VZ, Libby P. Obesity, Inflammation, and atherosclerosis. Nat Rev Cardiol 2009; 6: 399-409.
26. Ilán-Gómez F, González-Ortega M, Orea-Soler I, et al. Obesity and inflammation: change in adiponectin, C-reactive protein, tumour necrosis factor-alpha and interleukin-6 after bariatric surgery. Obes Surg 2012; 22: 950-5.
27. Arnardottir ES, Máslín G, Schwab RJ, et al. Interactions of inflammation and coagulation after long-term coronary artery disease. N Engl J Med 2005; 352: 1685-95.
28. Wannamethee SG, Whincup PH, Rumley A, Lowe GD, Lowe GD, Lowe GD. Inter-relationships of interleukin-6, cardiovascular risk factors and the metabolic syndrome among older men. J Clin Endocrinol Metab 2001; 86: 1154-9.
29. Warnberg J, Moreno LA, Mesana MI, Marcos A; The AVENA Group. Inflammatory mediators in overweight and obese Spanish adolescents. The AVENA Study. Int J Obes 2004; 28: S59-63.
30. Pradhan A, Manson J, Rifai N, Buring J, Ridker P. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 682: 327-34.
31. Yang M, Rifai N, Meir J, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-72.
32. Wang S, Liu Q, Wang J, Harnish DC. Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists. Biochem Biophys Res Commun 2009; 379: 476-9.
33. Pradhan A, Manson J, Rifai N, Buring J, Ridker P. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 682: 327-34.
34. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of interleukin 6 (IL-6) and tumor necrosis factor-alpha in patients with depression: preliminary findings. J Psychiatr Res 2005; 87: 1921-7.
35. Fujishima S, Watanabe H, Kawaguchi M, et al. Involvement of IL-17F via the induction of IL-6 in psoriasis. Arch Dermatol Res 2010; 302: 499-505.
36. Gluba A, Mikhailidis DP, Lip GY, Hannam S, Rysz J, Banach M. Metabolic syndrome and renal disease. Int J Cardiol 2013; 164: 141-50.
37. Matura LA, Ventetuolo CE, Palevsky HI, et al. Interleukin-6 and tumor necrosis factor-alpha are associated with quality of life-related symptoms in pulmonary arterial hypertension. Ann Am Thorac Soc 2015; 12: 370-5.
38. Zhou B, Liu J, Wang Z, Xi T. C-reactive protein, interleukin 6 and lung cancer risk: a meta-analysis. PLoS One 2012; 7: e43075.
39. Arai O, DeClerck Y. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 2010; 46: 1223-31.
40. Gluba A, Mikhailidis DP, Lip GY, Hannam S, Rysz J, Banach M. Metabolic syndrome and renal disease. Int J Cardiol 2013; 164: 141-50.
41. Fujishima S, Watanabe H, Kawaguchi M, et al. Involvement of IL-17F via the induction of IL-6 in psoriasis. Arch Dermatol Res 2010; 302: 499-505.
42. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther 2006; 8: S3.
43. Di Cesare PE, Chang E, Preston CF, Liu CJ. Serum interleukin-6 as a marker of periarticular infection following total hip and knee arthroplasty. J Bone Joint Surg Am 2005; 87: 1921-7.
44. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005; 2005: 273-9.
45. Musselman D, Miller A, Porter M, et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry 2001; 158: 1252-7.
46. Wirtz DC, Heller KD, Mittler O, Zilkens KW, Wolff JM. Interleukin-6: a potential inflammatory marker after total joint replacement. Int Orthop 2000; 24: 194-6.
47. Elder JT, Sartor CI, Boman DK, Benrazavi S, Fisher GI, Pittelkow MR. Interleukin-6 in psoriasis: expression and mitogenicity studies. Arch Dermatol Res 1992; 284: 324-32.
52. Backes JM, Howard PA, Moriarty P. Role of C-reactive protein in cardiovascular disease. Ann Pharmacother 2004; 38: 110-8.

53. Ishii S, Karamangla A, Bote M, et al. Gender, obesity and repeated elevation of C-reactive protein: data from the CARDIA Cohort. PLoS One 2012; 7: e36862.

54. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.

55. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-97.

56. Kasapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammation markers: a systematic review. J Am Coll Cardiol 2005; 45: 1563-9.

57. Ledue TB, Rifai N. Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. Clin Chem 2003; 49: 1258-71.

58. Wang CH, Li SH, Weisel RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003; 107: 1783-90.

59. Vadakayil AR, Dandekeri S, Kambil SM, Ali NM. Role of C-reactive protein as a marker of disease severity and cardiovascular risk in patients with psoriasis. Indian Dermatol Online J 2015; 6: 322-5.

60. Takahashi H, Inuma S, Honma M, Iizuka H. Increased serum C-reactive protein level in Japanese patients of psoriasis with cardio- and cerebrovascular disease. J Dermatol 2014; 41: 981-5.

61. Ma A, Pan X, Xing Y, Wu M, Wang Y, Ma C. Elevation of serum CXCL16 level correlates well with atherosclerotic ischemic stroke. Arch Med Sci 2014; 10: 47-52.

62. Köşüş N, Köşüş A, Turhan N. Relation between abdominal subcutaneous fat tissue thickness and inflammatory markers during pregnancy. Arch Med Sci 2014; 10: 739-45.

63. Kurtoglu E, Korkmaz H, Akturk E, Yılmaz M, Altas Y, Uckan A. Association of mitral annulus calcification activity in rheumatoid arthritis with serum concentration of C-reactive protein and erythrocyte sedimentation rate. J Rheumatol 1981; 9: 224-8.

64. Brooks GC, Blaha MJ, Blumenthal RS. Association between C-reactive protein, anthropometric and other metabolic parameters in Indian American women transitioning to premenopause. Menopause 2014; 21: 1290-6.

65. Devaraj S, Yun J, Adamson G, Galvez J, Jialal I. C-reactive protein impairs the endothelial glycocalyx resulting in endothelial dysfunction. Cardiovasc Res 2009; 84: 479-84.

66. Cirillo P, Sautin Y, Kanellis J, et al. Systemic inflammation, metabolic syndrome and progressive renal disease. Nephrol Dial Transplant 2009; 24: 1384-7.

67. Hubel C, Powers R, Sneded S, et al. CRP is elevated 30 years after eclamptic pregnancy. Hypertension 2008; 51: 1499-505.

68. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev 2006; 15: 381-4.

69. Eriinger TP, Platz EA, Rifai N, Helzlsouer K. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004; 291: 585-90.

70. Seddon J, Gensler C, Milton R, Klein M, Rifai N. Association between C-reactive protein and age-related macular degeneration. JAMA 2004; 291: 704-10.

71. Russell AI, Graham DC, Shepherd C, et al. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 2004; 13: 137-47.

72. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290: 2945-51.

73. Stuveling EM, Hillege HL, Bakker S, Gans R, de Jong PE, de Zeew E. C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int 2003; 63: 654-61.

74. Ridker PM. C-reactive protein: a simple test to help predict risk of heart attack and stroke. Circulation 2003; 108: e81-5.

75. Danesh J, Mokdad A. Prevalence of high C-reactive protein in persons with serum lipid concentrations by age in community-dwelling persons. Ann Clin Biochem 2013; 50: 457-64.

76. Woodard G, Mehta V, Mackey R, et al. C-reactive protein in young adults is associated with abnormal lung function in middle age. PLoS One 2010; 5: e11431.

77. Devaraj S, Yun J, Adamson G, Galvez J, Jialal I. C-reactive protein impairs the endothelial glycocalyx resulting in endothelial dysfunction. Cardiovasc Res 2009; 84: 479-84.

78. Klisic A, Vasiljevic N, Simic T, Djukic T, Maksimovic M, Matic M. Association between C-reactive protein, anthropometric and lipid parameters among healthy normal weight and overweight postmenopause women in Montenegro. Lab Med 2014; 45: 12-6.

79. Dayal D, Jain H, Attri S, Bhalla A. Relationship of high sensitivity C-reactive protein levels to anthropometric and other metabolic parameters in Indian children with normal weight and overweight. J Clin Diagn Res 2014; 8: PC05.

80. Kawamoto R, Kusunoki T, Abe M, Kohara K, Miki T. An association between body mass index and high-sensitivity C-reactive protein concentrations is influenced by age in community-dwelling persons. Ann Clin Biochem 2013; 50: 457-64.

81. Adjani UA, Ford E, Mokdad A. Prevalence of high C-reactive protein in persons with serum lipid concentra-
tions within recommended values. Clin Chem 2004; 50: 1618-22.

87. Khand F, Shaikh SS, Ata MA, Shaikh SS. Evaluation of the effect of smoking on complete blood counts, serum C-reactive protein and magnesium levels in healthy adult male smokers. J Pak Med Assoc 2015; 65: 59-61.

88. Libby P, Ridker P, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.

89. Swiatkiewicz I, Kozinski M, Magielski P, et al. Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction. Inflamm Res 2012; 61: 725-34.

90. Van Leeuwen WA, Lehto M, Karisola P, et al. Sleep restriction increases the risk of developing cardiovascular diseases by augmenting proinflammatory responses through IL-17 and CRP. PLoS One 2009; 4: e4589.

91. Shippur S, Gallo L, Crouse J, Allison M. The association between chronic stress type and C-reactive protein in the Multi-Ethnic Study of Atherosclerosis (MESA): does gender make a difference? J Behav Med 2012; 35: 74-85.

92. Kwon YS, Chi Sy, Shin HJ, et al. Plasma C-reactive protein and endothelin-1 level in patients with chronic obstructive pulmonary disease and pulmonary hypertension. J Kor Med Sci 2010; 25: 1487-91.

93. Forman BM, Goode E, Chen J, et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995; 81: 687-93.

94. Rader DJ. Liver X receptor and farnesoid X receptor as therapeutic targets. Am J Cardiol 2007; 100: S15-9.

95. Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science 1999; 284: 1362-5.

96. Evans MJ, Mahaney PE, Zhang S, et al. A synthetic farnesoid X receptor agonist protects against diet-induced dyslipidemia. Circulation 2007; 116: II-106.

97. Li J, Wilson A, Kuruba R, et al. FXR-mediated regulation of cytokine-induced C-reactive protein gene expression by liver X receptor. Circ Res 2006; 99: e88-99.

98. Matsuda M, Shimomura I, Sata M, et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipovascular axis. J Biol Chem 2002; 277: 37487-91.

99. Baratta R, Amato S, Degano C, et al. Adiponectin relation of C-reactive protein with diabetes. Br J Med Pract 2014; 7: e729.

100. Dekker JM, Funahashi T, Nijpels G, et al. Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab 2008; 93: 1489-96.

101. Ryo M, Nakamura T, Kihara S, et al. Prognostic value of adiponectin for cardiovascular disease: state of the art? Am J Physiol Heart Circ Physiol 2007; 292: H1655-63.

102. Nakamura Y, Shimada K, Fukuda D, et al. Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart 2004; 90: 528-33.

103. Ouedraogo R, Wu X, Xu SQ, et al. Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a CAMP signaling pathway. Diabetes 2006; 55: 1840-6.

104. Harmaneey R, Wilson C, Taegtmeyer H. Adaptation and maladaptation of the heart in obesity. Hypertension 2008; 52: 181-7.

105. Park S, Kim DS, Kwon DY, Yang HJ. Long-term central infusion of adiponectin improves energy and glucose homeostasis by decreasing fat storage and suppressing hepatic gluconeogenesis without changing food intake. J Neuroendocrinol 2011; 23: 687-98.

106. Matsuzawa Y. The metabolic syndrome and adipokines. FEBS Lett 2006; 580: 2917-21.
ta-analysis of prospective studies. Obes Rev 2013; 14: 555-67.
127. Kim DH, Kim C, Ding E, Townsend M, Lipsitz L. Adiponectin levels and the risk of hypertension: a systematic review and meta-analysis. Hypertension 2013; 62: 27-32.
128. Biaslov K, Bulum T, Zibar K, Duvnjak L. Relationship between adiponectin level, insulin sensitivity, and metabolic syndrome in type 1 diabetic patients. Int J Endocrinol 2013; 2013: 535906.
129. Kim SY, Lee SJ, Park H, et al. Adiponectin is associated with impaired fasting glucose in the non-diabetic population. Epidemiol Health 2011; 33: e2011007.
130. Ho DY, Cook NR, Britton KA, et al. High-molecular-weight and total adiponectin levels and incident symptomatic peripheral artery disease in women. Circulation 2011; 124: 2303-11.
131. Li S, Shin HI, Ding EL, van Dam R. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009; 302: 179-88.
132. Greif M, Becker A, von Ziegler F, et al. Pericardial adipose tissue determined by dual source CT is a risk factor for coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2009; 29: 781-6.
133. Marso SP, Mehta SK, Frutkin A, House JA, McCrary JR, Kullarni KR. Low adiponectin levels are associated with atherogenic dyslipidemia and lipid-rich plaque in nondiabetic coronary arteries. Diabetes Care 2008; 31: 989-94.
134. Qasim A, Mehta NN, Tadesse MG, et al. Adipokines, insulin resistance and coronary artery calcification. J Am Coll Cardiol 2008; 52: 231-6.
135. Hanley AG, Bowden D, Wagenknecht LE, et al. Associations of adiponectin with body fat distribution and insulin sensitivity in nondiabetic Hispanics and African-Americans. J Clin Endocrinol Metab 2007; 92: 2665-71.
136. Frystyk J, Berne C, Berglund L, Jensevik K, Flyvbjerg A, Zethelius B. Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab 2007; 92: 571-6.
137. Badawi A, Klip A, Haddad P, et al. Type 2 diabetes mellitus and inflammation: prospects for biomarkers of risk and nutritional intervention. Diabetes Metab Syndr Obes 2010; 3: 173-86.